Eisai announced that Fycompa (perampanel) tablets are now available. Fycompa, a Schedule III antiepileptic, was approved in October 2012 for the treatment of partial onset seizures with or without secondarily generalized seizures in patients >12 years old.
Fycompa is a non-competitive AMPA glutamate receptor antagonist on post-synaptic neurons. Glutamate is the primary excitatory neurotransmitter in the central nervous system and is involved in a number of neurological disorders caused by neuronal over-excitation. The exact mechanism of Fycompa’s antiepileptic effects has not been fully elucidated.
Fycompa is supplied as 2mg, 4mg, 6mg, 8mg, 10mg, and 12mg film-coated tablets in 30- and 90-count bottles.
For more information call (888) 422-4743 or visit Fycompa.com.